Caris Life Sciences Inc at JPMorgan Healthcare Conference Transcript
Great. Welcome back from lunch, everyone. My name is Sebastian Sandler from the Life Science Tools and Diagnostics team at JPMorgan. I'm pleased to be joined by the Caris Life Sciences team. As usual, there will be 20 or so minutes presentation followed by Q&A.
And so with that, I'll kick it off to the team to get things going.
Great. Sebastian, thank you. I'm Brian Brille, I'm Vice Chairman of Caris Life Sciences. I'm joined by David Spetzler, who is our President; as well as Luke Power, our Chief Financial Officer. So Spetz and I were just commenting, we presented here for many years, but this is our first year as a publicly-traded company. So thank you all very much who have supported us.
We went public, as you know, in June of last year, and I thought it was sort of appropriate to start by reflecting on sort of where we are. We thought that for us, 2025 was a very important year, a year of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
